THRB and metabolic dysfunction-associated steatohepatitis: Until Madrigal Pharmaceuticals’ very recent breakthrough in March 2024 with Resmetirom’s approval for MASH treatment in the United States (US), a selective thyroid hormone receptor-β (THR-β) agonist, there have been no approved pharmacotherapies for the treatment of MASH, forcing patients to primarily rely on general lifestyle interventions (e.g., diet, exercise) [6,8].